Now Available From Dey Pharma, L.P.

EMSAM®
(selegiline transdermal system)

Description	NDC #	How Supplied
EMSAM® **(selegiline transdermal system)**	**6 mg** 49502-900-30 **9 mg** 49502-901-30 **12 mg** 49502-902-30	**1 box of 30 Transdermal Systems**

- Dey Pharma, L.P. is now marketing EMSAM, the only MAOI patch indicated for the treatment of major depressive disorder
- The recommended starting dose of EMSAM is 6 mg/24 hr administered once daily as a transdermal patch
  - No dietary restrictions at recommended starting dose of 6 mg/24 hr
  - EMSAM is also available in 9 mg/24 hr and 12 mg/24 hr once daily doses as a transdermal patch
  - Dietary modifications required at 9 mg/24 hr and 12 mg/24 hr to reduce the risk of hypertensive crisis

Wholesaler Order Numbers

AmerisourceBergen	
EMSAM Strength/Dose	**Order Number**
6 mg	**030-429**
9 mg	**062-796**
12 mg	**006-817**

Cardinal Health	
EMSAM Strength/Dose	**Order Number**
6 mg	**4251039**
9 mg	**4262762**
12 mg	**4246195**

McKesson Corp	
EMSAM Strength/Dose	**Order Number**
6 mg	**1243898**
9 mg	**1777879**
12 mg	**1243559**

EMSAM (selegiline transdermal system) is indicated for the treatment of major depressive disorder.

To reduce the risk of hypertensive crisis, which is potentially life-threatening, foods and beverages high in tyramine must be avoided while on EMSAM® 9 mg/24hr or 12 mg/24hr, and for 2 weeks following discontinuation of EMSAM® at these doses, or reducing the dose to EMSAM® 6mg/24hr.

- **EMSAM®** should not be used with **tyramine-containing nutritional supplements**

Due to potential for **serotonin syndrome**, which is sometimes fatal, EMSAM® should not be used with: SSRIs; SNRIs; TCAs; MAOIs; cyclobenzaprine; mirtazapine; bupropion; meperidine; tramadol, methadone, propoxyphene, and pentazocine; dextromethorphan or St. John's Wort; oral selegiline.

Important Safety Information

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of EMSAM or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised for the need for close observation and communication with the prescriber. EMSAM is not approved for use in pediatric patients. Furthermore, EMSAM at any dose should not be used in children under the age of 12, even when administered with dietary modifications. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)

Please click here for full Prescribing Information, including Boxed WARNING.

If you have any questions about EMSAM,
please call 1-800-395-3376
or visit www.dey.com.

Distributed by DEY A Mylan Company

Manufactured for Somerset PHARMACEUTICALS, INC.

U9-365-00 12/09 Printed in USA